Articles tagged with Mapk Signaling
A new drug targeting RAS, a pathologically altered protein causing 40% of colorectal and 90% of pancreatic cancers, has been developed. The molecular eraser, RIBOTAC, stops the production of RAS by degrading its mRNA, but surprisingly triggers changes in cancer cells despite minimal impact on protein quantity.
Early gastric cancer cells become self-sufficient by producing WNT7B, creating a self-sustaining loop and activating WNT signaling internally. This mechanism is triggered by MAPK signaling activation and has been validated in genetically engineered mouse models and human patient-derived organoids.
The study reveals that the interplay between ERK/MAPK and IFN-gamma signaling is essential for preserving intestinal stem cells during aging. The researchers found that maintaining a balance between these signaling pathways is critical for supporting stem cell maintenance, while also driving age-related changes in differentiated cells.
Researchers discuss diverse BRAF alterations found in human cancers and strategies to inhibit them. Class I BRAF inhibitors represent a landmark achievement in precision oncology, with FDA-approved dabrafenib/trametinib for metastatic BRAF p.V600E-mutant solid tumors.
Researchers explore Extracellular signal-regulated kinase 5 (Erk5) and its unique structures regulating autophosphorylation and transcription. Erk5 is involved in angiogenesis, neurogenesis, energy metabolism, tumor growth, and metastasis, making it a potential target for cancer treatment.
Researchers have made significant progress in understanding the enzyme SMYD3's involvement in prostate cancer's progression to a more aggressive stage. The study found that adding methyl groups to the MAP kinase protein is likely SMYD3's role in driving metastasis, and compounds that can inactivate SMYD3 are already available
Researchers found a partial response in a patient with pancreatic acinar cell carcinoma, as well as stable disease in 11 patients, when combining riluzole with sorafenib in a phase I trial. The combination was safe and tolerable, and further exploration of its potential is warranted.
A University of Colorado Cancer Center study found TAK-733 to be highly active against colorectal cancer cells and tumors, with 42 of 54 cell lines sensitive to the drug. However, inconsistent absorption and bioavailability were observed, raising concerns about safety and tolerability.
Researchers have discovered that pilocytic astrocytomas, a common childhood brain tumor, arise from defective activation of the MAPK signaling pathway. The study provides new insights into the disease and potential targets for treatment, including targeted agents to block overactive MAPK signaling.
Three independent studies demonstrate that hyperactivation of MAPK signaling pathways underlies NF1-associated disorders. Researchers found that inhibiting MEK and ERK can block the development of JMML, reduce the growth of peripheral nerve tumors, and ameliorate myeloproliferative disorders in NF1 mutant mice.
A Princeton University-led research team discovered that protein competition for an enzyme provides a mechanism to integrate different signals directing early embryonic development. This competition influences which signals are sent to cells, establishing a biochemical mode of signal integration.
Researchers at the University of Illinois Chicago have discovered a signaling mechanism in yeast cells that controls cell growth and differentiation, with potential implications for cancer treatment. The study found that pheromone triggers cells to stop dividing and orient their growth toward the source of pheromone.